Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Zogenix Sees Its Pipeline Drugs Continue to Be Developed in Japan after UCB Deal
Zogenix CEO Stephen Farr recently sat with Jiho to share the company’s plan for its Japan business at this point as it awaits the closing of a pending acquisition by UCB. The US biotech hopes to continue the Japan development…
To read the full story
Related Article
- Zogenix Files Dravet Syndrome Drug in Japan
December 23, 2021
- US Biotech Zogenix Launches Japan Arm, Dravet Syndrome Med Filing Eyed in 2021
June 11, 2021
- Nippon Shinyaku Licenses Dravet Syndrome Treatment from Zogenix
March 22, 2019
BUSINESS
- Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
- Espha Launches Generic Forxiga; Nipro AG Due in September
July 6, 2026
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…